However, with growing evidence that ATM germline PV carriers are at risk of developing cancer, it may be worth considering germline testing to determine whether the variants detected by tumor sequencing are of germline or somatic origin, particularly in patients with breast, pancreatic, prostate, ovarian cancer, or melanoma. This evidence concerns the gene ATM and ovarian cancer.